The Race for a Coronavirus Vaccine

Will compressed and overlapping steps get a vaccine faster?

This graphic compares a conventional timeline for vaccine development, anticipating a COVID-19 vaccine available by May 2036, versus the accelerated goal of developing, producing and distributing a vaccine much, much faster. Excerpted from Five “P”s to Watch.

COVID-19 Vaccine Pipeline Snapshot

A snapshot of the COVID-19 vaccine pipeline. Excerpted from Five “P”s to Watch.

Vaccines Approaches in COVID-19 Vaccine Development

HIV represents one of the most challenging viruses ever encountered. Though an HIV vaccine has yet to be licensed, vaccine science has made enormous strides as it confronts this rapidly-mutating virus. Years of painstaking work to develop vaccines for HIV are now making possible the record-breaking timelines that researchers aspire to for the development of COVID-19 vaccines. Vaccines research has generated more scientific knowledge about immune function and responses than ever existed. And key vaccine platforms are fast-tracking the development and testing of experimental vaccines for COVID-19 today.

Excerpted from Five “P”s to Watch.

A Global Pandemic Requires an Unprecedented Response

Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.

Excerpted from Five “P”s to Watch.

The Race for a Coronavirus Vaccine

Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.

Excerpted from Five “P”s to Watch.

Leveraging the Vaccines Enterprise for COVID-19 Vaccine Research

In many ways, the collaborative research movement grew up around Vaccines. Thanks in large part to HIV advocacy, out-of date research models that were competitive and closed-door are increasingly yielding to more transparent and collaborative research and development efforts—in both the HIV and COVID-19 responses.

Building on big science partnerships, data sharing and collaboration pioneered over the last 15 years of Vaccines research and development, global initiatives are marshalling the talents, experiences and resources of key stakeholders. And just as HIV laid the foundation for more effective partnerships in research, lessons from the COVID-19 experience can also inspire greater collaboration and broader involvement by a range of players in the vaccines research effort.

Excerpted from 5 “P”s to Watch.

Vaccine Efficacy Trials Pipeline

This infographic shows a timeline for each of the three major vaccine efficacy trials proposed or underway now.

Vaccines Research Pipeline

This graphic shows the many types of Vaccines undergoing research, categorized by the immune response they are designed to elicit—broadly neutralizing antibodies, non-neutralizing antibodies, T-cell responses or a combination of these.

AVAC’s “3D” View of the World: 2019 and beyond

This infographic lays out AVAC’s top-line recommendations from AVAC Report 2019: Now What? The recommendations fall into three categories: deliver — prevention programs whose impact is well-measured and -defined; demonstrate — next-generation engagement for next-generation trials; develop — new targets for the post-2020 world.

UNAIDS Fast-Track Targets: The plan and the progress

The most widely-known UNAIDS Fast-Track goals were the 90-90-90 targets focused on diagnosing people with HIV, linking them to ART and supporting them to achieve virologic suppression. But these were only part of what the UNAIDS modelers said was needed to reduce new HIV diagnoses to 500,000 per year; the model also included significant scaling up of primary prevention including the targets listed below. There are gaps across the board, which helps explain how the world fell short of the hoped-for reduction in new HIV diagnoses.

Excerpted from AVAC Report 2019: Now What?